View the NewsRx Library

Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Google 2009 PageRank: #2 Among Top Health News and Media Publications

Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology

Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals

Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This site complies with the HONcode standard for trustworthy health information:
verify here.

Clinical Trials Week

Susan Hasty, Publisher
Table of Contents . . . July 20th, 2009
Non-Subscriber - Summaries Only
Related Areas: Other Issues in Clinical Trials Week | Other Publications

ARYx Therapeutics, Inc. - ARYx Therapeutics Announces Results of Phase 2/3 Clinical Trial on Anticoagulant Agent Tecarfarin

Cancer - Research reports from University of Oxford provide new insights into cancer

Cancer Vaccines - New cancer vaccines study findings recently were reported by J.A. Kyte and co-researchers

Herpes Zoster Virus - Reports from A.K. Satyaprakash and colleagues advance knowledge in herpes zoster virus

Leukemia - Data from University of Tokyo advance knowledge in leukemia

Life Sciences - Reports on life sciences findings from W. Ingram and co-researchers provide new insights

Life Sciences - Study results from J. Romano and colleagues broaden understanding of life sciences

Malt Lymphoma - Research on malt lymphoma described by scientists at Harvard University

Melanoma - Research from D. Yip and co-researchers in the area of melanoma described

Myeloma - Research from Gunma University broadens understanding of myeloma

Myeloma - Study findings from Washington University broaden understanding of myeloma

Alcon, Inc. - Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction

Array BioPharma Inc. - Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials

Arthritis - Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

BioLineRx Ltd. - Ikaria® to In-License BioLineRx's BL-1040

Biotechnology Business - IKARIA(R) to In-License BioLineRx's BL-1040

Breast Cancer - Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

Carcinoid - Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

Geron Corporation - Geron Scientists and Collaborators Publish Data Showing Functional Dendritic Cells Can Be Derived from Human Embryonic Stem Cells Using Scalable Production Methods

GTx, Inc. - GTx-758, an Oral LH Inhibitor for First Line Treatment of Advanced Prostate Cancer, Advances into Second Phase I Clinical Trial

Heart Failure - Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement

Merck & Co., Inc. - Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease

Millennium - CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer

Obesity and Diabetes - Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

Pain Management - Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment

Pediatrics - MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

Peplin, Inc. - Peplin Completes Enrolment in its Phase 3 Clinical Trials for PEP005 Gel in AK on the Face and Scalp

Portola Pharmaceuticals, Inc. - Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress

Revance Therapeutics, Inc. - Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type a for the Treatment of Facial Wrinkles

Synergy Pharmaceuticals, Inc. - Synergy Pharmaceuticals Raises $7.09 Million in Common Stock Financing

Therapy - Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action

Return to Top of Page


Home \| Free Newsletters \| Products \| Article Library \| About Us \| Contact \| Privacy Policy \| Search \| Visit VerticalNews.com Copyright © 2009 NewsRx